David Bishop

David Bishop

Auto-generated profile, based on publicly available information

David Bishop

Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2021 in Blood
Verified
Journal Article
Closed access
PDF file
DBDavid C. Bishop
David C. Bishop
LCLeighton E. Clancy
Leighton E. Clancy
RSRenee Simms
Renee Simms
JBJane Burgess
Jane Burgess
GMGeetha Mathew
Geetha Mathew
KMKenneth Paul Micklethwaite
Kenneth Paul Micklethwaite
Key Points. Matched sibling donor-derived piggyBac CAR T-cells showed 100% CR rate against CD19+ malignancy relapsed/refractory following allo-HSCT.Two cases of

2 November 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
BWBarbara Withers
Barbara Withers
EBEmily Blyth
Emily Blyth
LCLeighton E. Clancy
Leighton E. Clancy
AYAgnes Yong
Agnes Yong
CFChris Fraser
Chris Fraser
DGDavid J. Gottlieb
David J. Gottlieb
Key Points: Partially HLA-matched third-party CMV-specific T cells provide long-term viral control in HSCT patients with resistant CMV infection. Viral control occurs in the setting of recovery of CD8+ terminally differentiated effector T cells.

1 September 2015 in Cytotherapy
Verified
Journal Article
Closed access
SRSaumya Ramanayake
Saumya Ramanayake
IBIan Bilmon
Ian Bilmon
DBDavid Bishop
David Bishop
MDMing-Celine Dubosq
Ming-Celine Dubosq
EBEmily Blyth
Emily Blyth
KMKenneth Micklethwaite
Kenneth Micklethwaite

1 August 2018 in Molecular Therapy
Verified
Journal Article
Open access
DBDavid C. Bishop
David C. Bishop
NXNing Xu
Ning Xu
BTBenjamin Tse
Benjamin Tse
TOTracey A. O’brien
Tracey A. O’brien
DGDavid J. Gottlieb
David J. Gottlieb
KMKenneth P. Micklethwaite
Kenneth P. Micklethwaite
Clinical trials of CD19-specific chimeric antigen receptor (CAR19) T cells have demonstrated remarkable efficacy against relapsed and refractory B cell malignancies. The piggyBac transposon system offers a less complex and more economical means for generating CAR19 T cells compared to viral vectors. We have previously optimized a protocol for the generation of CAR19 T cells using the piggyBac system, but we found that CAR19 T cells had poor in vivo efficacy and persistence, probably due to deleterious FcγR interactions with the CAR's IgG1 Fc-containing spacer domain. We therefore designed three CD19-specifc CARs that lacked the IgG1 Fc region, and we incorporated combinations of CD28 or 4-1BB transmembrane and co-stimulatory domains. PiggyBac-generated CAR19 T cells expressing these re-designed constructs all demonstrated reactivity in vitro specifically against CD19+ cell lines. However, those combining CD28 transmembrane and co-stimulatory domains showed CD4 predominance and inferior cytotoxicity. At high doses, CAR19 T cells were effective against B-ALL in a xenograft mouse model, regardless of co-stimulatory domain. At diminishing doses, 4-1BB co-stimulation led to greater potency and persistence of CAR19 T cells, and it provided protection against B-ALL re-challenge. Production of potent CAR T cells using piggyBac is simple and cost-effective, and it may enable wider access to CAR T cell therapy.

1 April 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JTJeremy Turner
Jeremy Turner
HNHannah Nicholas
Hannah Nicholas
DBDavid Bishop
David Bishop
JMJacqueline M. Matthews
Jacqueline M. Matthews
MCMerlin Crossley
Merlin Crossley
The ability of DNA-binding transcription factors to recruit specific cofactors is central to the mechanism by which they regulate gene expression. BKLF/KLF3, a member of the Krüppel-like factor family of zinc finger proteins, is a potent transcriptional repressor that recruits a CtBP co-repressor. We show here that BKLF also recruits the four and a half LIM domain protein FHL3. Different but closely linked regions of BKLF mediate contact with CtBP2 and FHL3. We present evidence that CtBP2 also interacts with FHL3 and demonstrate that the three proteins co-elute in gel filtration experiments. CtBP and FHL proteins have been implicated in both nuclear and cytoplasmic functions, but expression of BKLF promotes the nuclear accumulation of both FHL3 and CtBP2. FHL proteins have been shown to act predominantly as co-activators of transcription. However, we find FHL3 can repress transcription. We suggest that LIM proteins like FHL3 are important in assembling specific repression or activation complexes, depending on conditions such as cofactor availability and promoter context.

27 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
RLRaymond Hall Yip Louie
Raymond Hall Yip Louie
CCCurtis Cai
Curtis Cai
JSJerome Samir
Jerome Samir
MSMandeep Singh
Mandeep Singh
IDIra W. Deveson
Ira W. Deveson
FLFabio Luciani
Fabio Luciani
Chimeric antigen receptor (CAR) T cell therapy is effective in treating B cell malignancies, but factors influencing the persistence of functional CAR+ T cells, such as product composition, patients’ lymphodepletion, and immune reconstitution, are not well understood. To shed light on this issue, here we conduct a single-cell multi-omics analysis of transcriptional, clonal, and phenotypic profiles from pre- to 1-month post-infusion of CAR+ and CAR− T cells from patients from a CARTELL study (ACTRN12617001579381) who received a donor-derived 4-1BB CAR product targeting CD19. Following infusion, CAR+ T cells and CAR− T cells shows similar differentiation profiles with clonally expanded populations across heterogeneous phenotypes, demonstrating clonal lineages and phenotypic plasticity. We validate these findings in 31 patients with large B cell lymphoma treated with CD19 CAR T therapy. For these patients, we identify using longitudinal mass-cytometry data an association between NK-like subsets and clinical outcomes at 6 months with both CAR+ and CAR− T cells. These results suggest that non-CAR-derived signals can provide information about patients’ immune recovery and be used as correlate of clinically relevant parameters.